CL2015003801A1 - Formulaciones de anticuerpos y metodos - Google Patents
Formulaciones de anticuerpos y metodosInfo
- Publication number
- CL2015003801A1 CL2015003801A1 CL2015003801A CL2015003801A CL2015003801A1 CL 2015003801 A1 CL2015003801 A1 CL 2015003801A1 CL 2015003801 A CL2015003801 A CL 2015003801A CL 2015003801 A CL2015003801 A CL 2015003801A CL 2015003801 A1 CL2015003801 A1 CL 2015003801A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- antibody formulations
- antibody
- synucleipathy
- liofilized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843011P | 2013-07-04 | 2013-07-04 | |
| US201461979886P | 2014-04-15 | 2014-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003801A1 true CL2015003801A1 (es) | 2016-07-15 |
Family
ID=51355583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003801A CL2015003801A1 (es) | 2013-07-04 | 2015-12-31 | Formulaciones de anticuerpos y metodos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10513555B2 (enExample) |
| EP (2) | EP3524264A1 (enExample) |
| JP (3) | JP6404338B2 (enExample) |
| KR (1) | KR20160030247A (enExample) |
| CN (1) | CN105492019B (enExample) |
| AU (1) | AU2014285719A1 (enExample) |
| CA (1) | CA2917097C (enExample) |
| CL (1) | CL2015003801A1 (enExample) |
| CU (2) | CU20170039A7 (enExample) |
| ES (1) | ES2704440T3 (enExample) |
| IL (1) | IL243425A0 (enExample) |
| MX (1) | MX2016000201A (enExample) |
| PE (1) | PE20160868A1 (enExample) |
| PH (1) | PH12015502788A1 (enExample) |
| RU (1) | RU2016103079A (enExample) |
| SG (1) | SG11201510601TA (enExample) |
| WO (1) | WO2015001504A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
| CN108517010A (zh) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | 识别α-突触核蛋白的人源化抗体 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| MA42613A (fr) | 2015-08-13 | 2018-06-20 | Amgen Inc | Filtration en profondeur chargée de protéines de liaison à un antigène |
| RU2731418C2 (ru) * | 2015-09-28 | 2020-09-02 | Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. | Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине |
| CN105127166A (zh) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | 行走组件及具有其的光伏组件清洁装置 |
| CN109415440B (zh) * | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| US10889635B2 (en) * | 2016-11-15 | 2021-01-12 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| JP2021502955A (ja) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | シヌクレイン病の治療のための投与レジメン |
| US20190153102A1 (en) * | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| JP6831861B2 (ja) | 2019-01-25 | 2021-02-17 | 株式会社Ｇｒｉｎ | 歯科用測定器具、測定方法、及びアタッチメント器具 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
| GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| JP2023541048A (ja) | 2020-09-10 | 2023-09-27 | プロシーナ バイオサイエンシーズ リミテッド | パーキンソン病の処置 |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| CN117915952A (zh) | 2021-09-16 | 2024-04-19 | H.隆德贝克有限公司 | 用于治疗突触核蛋白病的组合物和方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| WO1996024369A1 (en) | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| JP4698950B2 (ja) | 2002-04-09 | 2011-06-08 | フラメル・テクノロジー | アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
| AU2003299498A1 (en) | 2002-05-13 | 2004-05-25 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| AU2006329963B2 (en) * | 2005-12-06 | 2011-06-09 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| SI2126093T1 (sl) | 2007-03-02 | 2013-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Izboljšanje priprave proteinov |
| WO2008116103A2 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| RU2500686C2 (ru) | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| DK2234600T3 (da) | 2007-12-21 | 2014-09-08 | Hoffmann La Roche | Antistofformulering |
| ES2544679T3 (es) | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Tratamiento y profilaxis de la amiloidosis |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| EP3521309A1 (en) | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| NZ713967A (en) | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
| CA2805112A1 (en) | 2010-07-15 | 2012-01-19 | Synovex Corporation | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| JP6023715B2 (ja) * | 2010-10-11 | 2016-11-09 | アッヴィ・バハマズ・リミテッド | タンパク質の精製方法 |
| WO2012109280A2 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| BR112013030472A2 (pt) * | 2011-06-30 | 2019-09-24 | Genentech Inc | formulação farmacêutica, artigo de fabricação e método |
| PE20191242A1 (es) * | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
| HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
| LT3091029T (lt) | 2011-10-31 | 2023-02-27 | F. Hoffmann-La Roche Ag | Anti-il13 antikūno kompozicijos |
| CN108517010A (zh) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | 识别α-突触核蛋白的人源化抗体 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| KR20190121874A (ko) | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
| US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/ja active Active
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/ru not_active Application Discontinuation
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/ko not_active Withdrawn
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/es unknown
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/es not_active Application Discontinuation
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 ES ES14752412T patent/ES2704440T3/es active Active
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/zh active Active
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en not_active Ceased
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/es unknown
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/es unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/es unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/ja active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CU20170039A7 (es) | 2017-06-05 |
| SG11201510601TA (en) | 2016-01-28 |
| EP3016677A2 (en) | 2016-05-11 |
| CU20160001A7 (es) | 2016-08-31 |
| JP2021020941A (ja) | 2021-02-18 |
| JP6404338B2 (ja) | 2018-10-10 |
| RU2016103079A (ru) | 2017-08-07 |
| US10513555B2 (en) | 2019-12-24 |
| US20150079074A1 (en) | 2015-03-19 |
| CN105492019A (zh) | 2016-04-13 |
| PH12015502788A1 (en) | 2016-03-21 |
| CN105492019B (zh) | 2020-02-11 |
| KR20160030247A (ko) | 2016-03-16 |
| WO2015001504A3 (en) | 2015-08-06 |
| IL243425A0 (en) | 2016-03-31 |
| CA2917097A1 (en) | 2015-01-08 |
| JP2016534052A (ja) | 2016-11-04 |
| ES2704440T3 (es) | 2019-03-18 |
| JP6854266B2 (ja) | 2021-04-07 |
| EP3524264A1 (en) | 2019-08-14 |
| AU2014285719A1 (en) | 2016-01-21 |
| WO2015001504A2 (en) | 2015-01-08 |
| EP3016677B1 (en) | 2018-12-19 |
| JP2019011339A (ja) | 2019-01-24 |
| HK1223544A1 (zh) | 2017-08-04 |
| US20200140534A1 (en) | 2020-05-07 |
| PE20160868A1 (es) | 2016-09-24 |
| CA2917097C (en) | 2022-05-03 |
| MX2016000201A (es) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016001895A1 (es) | Compuestos | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX375102B (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
| CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| EA201790032A1 (ru) | Бициклически замещённые урацилы и их применение | |
| UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
| EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| UY35745A (es) | Derivados sustituidos de fenilalanina |